Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Blue Water Biotech Acquires Proteomedix AG, A Private, Commercial-stage Diagnostics Oncology Company, In Stock Consideration; No Terms Disclosed

Author: Benzinga Newsdesk | December 18, 2023 08:08am

The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix and introduced a new name for the combined Company: Onconetix, Inc. Two members of Proteomedix' leadership team will become executives of Onconetix.

Posted In: BWV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist